Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 9,313-9,324 of 10,592
Drug study icon
CompletedNCT00228540

Satisfaction With Modafinil Treatment for ADHD

This study is completed in the United States. It is testing satisfaction With Modafinil Treatment for ADHD.

In United States
ADHDDrugA study involving a medication or substance.From 6 Years to 17 Years
Countries
United States
Sponsor
Cephalon
Condition
ADHD
Drug study icon
CompletedNCT05203341

NBI-1065845 for depression

This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing NBI-1065845 for depression.

In United States
DepressionDrugFrom 18 Years to 65 Years
Countries
United States, Bulgaria, Czechia, ...
Sponsor
Neurocrine Biosciences
Condition
Depression
Drug study icon
Active Not RecruitingNCT06029439

Safety and Effectiveness of NMRA-335140-501

This study is active but not recruiting in the United States, in France, in Canada, .... It focuses on Depression.

In United States
DepressionDrugFrom 18 Years to 65 Years
Countries
United States, France, Canada, ...
Sponsor
Neumora Therapeutics, Inc.
Condition
Depression
Drug study icon
CompletedNCT02411695

Safety study of Brexpiprazole (OPC- 34712) in schizophrenia

This study is completed in the United States. It is testing Brexpiprazole (OPC- 34712) for schizophrenia.

Remote / online
SchizophreniaDrugFrom 13 Years to 17 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02037074

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen for schizophrenia

This study is completed in the United States. It is testing Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Drug study icon
CompletedNCT00690274

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

This summary needs review. Please check the official study record and contact the research team for details.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.